- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06124131
Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening (BENEFIT-C)
The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. The main questions it aims to answer are:
- Do patient financial incentives for completing colorectal cancer screening increase screening completion?
- Does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for COVID-19 and flu shots increase completion of those shots?
Participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. Participants will be randomly assigned to either Group 1 or Group 2. Group 1 participants will be offered financial incentives for completing COVID-19 and flu shots within 2 months of enrollment. Group 2 participants will be offered financial incentives for completing a COVID-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment.
Researchers will compare to see if completion of a COVID-19 shot, a flu shot, and colorectal cancer screening is different between the two groups.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Erin M Peacock, PhD, MPH
- Phone Number: 504-988-1075
- Email: epeacoc@tulane.edu
Study Contact Backup
- Name: Laura M Perry, PhD
- Phone Number: 504-988-8906
- Email: lperry5@tulane.edu
Study Locations
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University School of Medicine
-
Contact:
- Erin M Peacock, PhD, MPH
- Phone Number: 504-988-1075
- Email: epeacoc@tulane.edu
-
Contact:
- Laura M Perry, PhD
- Phone Number: 504-988-8906
- Email: lperry5@tulane.edu
-
Principal Investigator:
- Marie A Krousel-Wood, MD, MSPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 45 to 75
- Receive care at participating primary care clinic
- Due for colorectal cancer screening
- Ability to understand and speak English
Exclusion Criteria:
- Currently participating in another clinical trial or research study on colorectal cancer screening
- Unable or unwilling to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Full financial incentives
$50/service patient financial incentive for completion of: COVID-19 shot, flu shot, colorectal cancer screening
|
$50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment
$50 incentive paid to participant for completion of flu shot within 2 months of enrollment
$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
|
Active Comparator: Partial financial incentives
$50/service patient financial incentive for completion of: COVID-19 shot, flu shot
|
$50 incentive paid to participant for completion of flu shot within 2 months of enrollment
$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in proportion of participants completing colorectal cancer screening between study arms
Time Frame: Two months
|
Completion of colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test as documented in electronic health record within two months of study enrollment
|
Two months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in proportion of participants completing COVID-19 shot between study arms
Time Frame: Two months
|
Completion of COVID-19 shot as documented in electronic health record within two months of study enrollment
|
Two months
|
Difference in proportion of participants completing flu shot between study arms
Time Frame: Two months
|
Completion of flu shot as documented in electronic health record within two months of study enrollment
|
Two months
|
Difference in proportion of participants completing at least one of the following services between study arms: colorectal cancer screening, COVID-19 shot, flu shot
Time Frame: Two months
|
Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, *OR* flu shot as documented in electronic health record within two months of study enrollment
|
Two months
|
Difference in proportion of participants completing all three services between study arms: colorectal cancer screening, COVID-19 shot, flu shot
Time Frame: Two months
|
Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, *AND* flu shot as documented in electronic health record within two months of study enrollment
|
Two months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients approached for recruitment
Time Frame: Three months
|
Number of patients with reachable phone numbers
|
Three months
|
Number of patients assessed for eligibility
Time Frame: Three months
|
Number of patients who begin eligibility screener
|
Three months
|
Number of patients randomized
Time Frame: Three months
|
Number of patients who consent and are randomized
|
Three months
|
Number of patients who receive intended treatment
Time Frame: Three months
|
Number of patients who complete outreach call
|
Three months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marie A Krousel-Wood, MD, MSPH, Tulane University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-1600-BENC
- OT2HL158287 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Financial incentive for colorectal cancer screening
-
Maria Sklodowska-Curie National Research Institute...Centre of Postgraduate Medical Education; Ministry of Health, PolandUnknown
-
US Department of Veterans AffairsCompleted
-
Virginia Commonwealth UniversityBlue Cross Blue Shield; Allina Health SystemCompletedColorectal Cancer Screening | Shared Decision MakingUnited States
-
University of California, DavisCalifornia Academy of Family PhysiciansCompletedColorectal NeoplasmsUnited States
-
Corporacion Parc TauliEnrolling by invitation
-
East Bay Institute for Research and EducationCompletedColorectal CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)Completed
-
University of PennsylvaniaCompleted
-
Harvard Medical School (HMS and HSDM)University of California, Berkeley; University of Southern CaliforniaWithdrawnReceipt of Radiology Studies | Receipt of Laboratory Tests
-
Mainz BiomedNot yet recruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma | Colorectal Polyp